AT7519M

DRUG3 trials

Sponsors

Astex Pharmaceuticals, Inc., NCIC Clinical Trials Group

Conditions

Chronic Lymphocytic LeukemiaMantle Cell LymphomaMultiple Myeloma

Phase 1

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

CompletedNCT01183949

Astex Pharmaceuticals, Inc.Multiple Myeloma

Start: 2010-11-30End: 2015-03-31Updated: 2024-08-02

Phase 2

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

CompletedNCT01627054

NCIC Clinical Trials GroupChronic Lymphocytic Leukemia

Start: 2012-08-27End: 2015-02-13Updated: 2023-08-04

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

CompletedNCT01652144

NCIC Clinical Trials GroupMantle Cell Lymphoma

Start: 2012-09-14End: 2015-02-13Updated: 2023-08-04